AVEO Pharmaceuticals Historical PE Ratio image   This AVEO PE ratio history page last updated 11/8/2022
AVEO Pharmaceuticals Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/7/2022
14.78-0.09-0.36NA
Q2 2022
8/4/2022
7.74-0.24-0.96NA
Q1 2022
5/5/2022
4.61-0.30-1.20NA
Q4 2021
3/14/2022
4.59-0.21-0.84NA
Q3 2021
11/8/2021
7.33-0.30-1.20NA
Q2 2021
8/5/2021
5.50-0.40-1.60NA
Q1 2021
5/10/2021
6.28-0.81-3.24NA
Q4 2020
3/16/2021
11.41-0.44-1.76NA
Q3 2020
11/9/2020
6.02-0.33-1.32NA
Q2 2020
8/10/2020
4.64-0.42-1.68NA
Q1 2020
4/30/2020
6.54-0.52-2.08NA
Q4 2019
3/16/2020
3.03-0.28-1.12NA
Q3 2019
11/12/2019
5.601.004.001.4
Q2 2019
8/8/2019
6.70-0.20-0.80NA
Q1 2019
5/9/2019
9.00-0.60-2.40NA
Q4 2018
3/14/2019
6.00-0.30-1.20NA
Q3 2018
11/9/2018
18.60-1.80-7.20NA
Q2 2018
8/7/2018
21.50-0.60-2.40NA
Q1 2018
5/8/2018
22.30-0.80-3.20NA
Q4 2017
3/13/2018
29.30-0.60-2.40NA
Q3 2017
11/7/2017
29.90-2.20-8.80NA
Q2 2017
8/9/2017
28.50-0.80-3.20NA
Q1 2017
5/4/2017
5.90-1.20-4.80NA
Q4 2016
3/22/2017
8.40-0.70-2.80NA
Q3 2016
11/4/2016
6.10-0.70-2.80NA
Q2 2016
8/4/2016
9.60-1.30-5.20NA
Q1 2016
5/10/2016
9.00-1.30-5.20NA
Q4 2015
3/15/2016
10.50-1.10-4.40NA
Q3 2015
11/9/2015
12.40-1.00-4.00NA
Q2 2015
8/10/2015
14.60-1.00-4.00NA
Q1 2015
5/7/2015
13.60-2.10-8.40NA
Q4 2014
3/6/2015
15.00-2.70-10.80NA
Q3 2014
11/5/2014
9.50-2.80-11.20NA
Q2 2014
8/11/2014
11.90-3.50-14.00NA
Q1 2014
5/7/2014
11.50-1.20-4.80NA
Q4 2013
3/13/2014
18.10-3.20-12.80NA
Q3 2013
11/7/2013
20.70-4.70-18.80NA
Q2 2013
8/8/2013
21.70-6.20-24.80NA
Q1 2013
4/29/2013
74.40-6.90-27.60NA
Q4 2012
2/13/2013
73.50-4.90-19.60NA
Q3 2012
10/30/2012
NA-6.90-27.60NA
Q2 2012
8/2/2012
97.50-6.80-27.20NA
Q1 2012
5/3/2012
115.50-7.70-30.80NA
AVEO Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/7/2022
14.78-0.09-0.84NA
Q2 2022
8/4/2022
7.74-0.24-1.05NA
Q1 2022
5/5/2022
4.61-0.30-1.21NA
Q4 2021
3/14/2022
4.59-0.21-1.72NA
Q3 2021
11/8/2021
7.33-0.30-1.95NA
Q2 2021
8/5/2021
5.50-0.40-1.98NA
Q1 2021
5/10/2021
6.28-0.81-2.00NA
Q4 2020
3/16/2021
11.41-0.44-1.71NA
Q3 2020
11/9/2020
6.02-0.33-1.55NA
Q2 2020
8/10/2020
4.64-0.42-0.22NA
Q1 2020
4/30/2020
6.54-0.52-0.00NA
Q4 2019
3/16/2020
3.03-0.28-0.08NA
Q3 2019
11/12/2019
5.601.00-0.10NA
Q2 2019
8/8/2019
6.70-0.20-2.90NA
Q1 2019
5/9/2019
9.00-0.60-3.30NA
Q4 2018
3/14/2019
6.00-0.30-3.50NA
Q3 2018
11/9/2018
18.60-1.80-3.80NA
Q2 2018
8/7/2018
21.50-0.60-4.20NA
Q1 2018
5/8/2018
22.30-0.80-4.40NA
Q4 2017
3/13/2018
29.30-0.60-4.80NA
Q3 2017
11/7/2017
29.90-2.20-4.90NA
Q2 2017
8/9/2017
28.50-0.80-3.40NA
Q1 2017
5/4/2017
5.90-1.20-3.90NA
Q4 2016
3/22/2017
8.40-0.70-4.00NA
Q3 2016
11/4/2016
6.10-0.70-4.40NA
Q2 2016
8/4/2016
9.60-1.30-4.70NA
Q1 2016
5/10/2016
9.00-1.30-4.40NA
Q4 2015
3/15/2016
10.50-1.10-5.20NA
Q3 2015
11/9/2015
12.40-1.00-6.80NA
Q2 2015
8/10/2015
14.60-1.00-8.60NA
Q1 2015
5/7/2015
13.60-2.10-11.10NA
Q4 2014
3/6/2015
15.00-2.70-10.20NA
Q3 2014
11/5/2014
9.50-2.80-10.70NA
Q2 2014
8/11/2014
11.90-3.50-12.60NA
Q1 2014
5/7/2014
11.50-1.20-15.30NA
Q4 2013
3/13/2014
18.10-3.20-21.00NA
Q3 2013
11/7/2013
20.70-4.70-22.70NA
Q2 2013
8/8/2013
21.70-6.20-24.90NA
Q1 2013
4/29/2013
74.40-6.90-25.50NA
Q4 2012
2/13/2013
73.50-4.90-26.30NA
Q3 2012
10/30/2012
NA-6.90NANA
Q2 2012
8/2/2012
97.50-6.80NANA
Q1 2012
5/3/2012
115.50-7.70NANA
Quotes delayed 20 minutes

Email EnvelopeFree AVEO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
AVEO Pharmaceuticals (AVEO) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

AVGR PE Ratio History
AVIR PE Ratio History
AVNS PE Ratio History
AVRO PE Ratio History
AVTE PE Ratio History
AVTX PE Ratio History
AVXL PE Ratio History
AWH PE Ratio History
AXDX PE Ratio History
AXGN PE Ratio History
How should the AVEO historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like AVEO Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this AVEO Historical PE Ratio page.

What is the average historical PE for AVEO based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The AVEO historical PE ratio using the annualized quarterly earnings method works out to 1.4.

What is the average historical PE for AVEO based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The AVEO historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the AVEO Pharmaceuticals Historical PE Ratio information for AVEO Pharmaceuticals' stock. The average AVEO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 1.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AVEO historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AVEO historical PE result, against the recent PE: when this page was posted on 11/7/2022, the most recent closing price for AVEO had been 14.78, and the most recent quarterly earnings result, annualized, was 4. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent AVEO PE on 11/7/2022 based on annualized quarterly EPS was 3.7. Based on AVEO's history, that recent PE is elevated relative to the historical average, with the recent PE 164.3% higher than the historical average PE across our data set for AVEO Pharmaceuticals.

For self directed investors doing their due diligence on AVEO or any other given stock, valuation analysis for AVEO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate AVEO Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AVEO. Thanks for visiting, and the next time you need to research AVEO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Financial Stocks Hedge Funds Are Buying, HSBC Stock Predictions, CCOI Historical Stock Prices.

 

AVEO Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.